A Targeted Thorium-227 Conjugate Demonstrates Efficacy in Preclinical Models of Acquired Drug Resistance and Combination Potential with Chemotherapeutics and Antiangiogenic Therapies.

Although there was a trend of a 27–34% lower accumulation in the groups where MSLN-TTC was combined with bevacizumab or regorafenib compared with the MSLN-TTC monotherapy group, the differences between the treatment groups did not reach statistical significance.

also in 111,027 other papers

MSLN-TTC, docetaxel and pegylated liposomal doxorubicin monotherapies showed a trend of slight increase in the DNA damage marker γH2AX compared with vehicle, but no additive increase was observed in the respective combination groups ( Fig. 3C ).

also in 53,322 other papers